Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
{{output}}
Background: The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic tri... ...
